Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience

Chimeric antigen receptor (CAR)-modified T cells targeting CD19 are under investigation for multiply relapsed or refractory CD19+  acute lymphoblastic leukemia (ALL) [1-5]. Because of unprecedented results, multisite trials conducted at centers throughout the United States and the world led to approval by the US Food and Drug Administration of the first CAR T cell product, tisagenlecleucel (formerly CTL019), in August 2017. This patient population has often already had significant exposure to potentially cardiotoxic agents, such as anthracycline treatment or total body irradiation (TBI), before receipt of CAR T cells.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research